FDA Approves TNKase To Treat Ischemic Strokes In Adults

Updated Mar 7, 2025 | 08:52 AM IST

SummaryIt is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion.
Ischemic Stroke

Credits: Canva

The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.

How is TNKase administered?

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.

How Was TNKase approved?

The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.

How Common Are These Strokes?

In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.

TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."

What Are The Symptoms Of Ischemic Strokes?

Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.

Other symptoms include:

  • Loss of coordination or clumsiness
  • Blurry vision or double vision
  • Dizziness or vertigo
  • Nausea and vomiting
  • Neck stiffness
  • Mood swings or sudden personality changes
  • Confusion or agitation
  • Seizures
  • Memory loss (amnesia)
  • Headaches which are sudden and severe
  • Passing out or fainting
  • Coma

Are There Any Warning Signs?

While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.

End of Article

After US Loses Measles Elimination Status, Senators Call Out RFK Jr. Over Vaccine Policies

Updated Nov 19, 2026 | 06:00 PM IST

SummaryThe Pan American Health Organization (PAHO) confirmed that the US had lost the status it maintained since 2000. ​The country has recorded more than 5,700 measles cases and 11 deaths. Pennsylvania, the hardest-hit state, has reported its eighth measles-associated death of 2026.
After US Loses Measles Elimination Status, Senators Call Out RFK Jr. Over Vaccine Policies

Credit: AP Photos

After 26 years, the US has lost its measles elimination status, marking a major setback for public health efforts. The resurgence has intensified criticism of Health and Human Services Secretary Robert F. Kennedy Jr. over his vaccine policies and rhetoric.

The Pan American Health Organization (PAHO) confirmed that the US had lost the status it maintained since 2000.

The country has recorded more than 5,700 measles cases and 11 deaths. Pennsylvania, the hardest-hit state, has reported its eighth measles-associated death of 2026.

Measles Infections Among Pregnant Women, Newborns Raise Concern

A CDC-led report identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns.

The actual number may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.

“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.

Decades of MMR vaccination meant many doctors had never encountered measles during their medical careers. However, declining vaccination rates have allowed the disease to spread in under-vaccinated communities.

US Senators Criticise RFK Jr.

Criticism of Kennedy has crossed party lines. Republican Senator Bill Cassidy of Louisiana on Sunday criticised what he called a "series of failures" under Kennedy's leadership at the Department of Health and Human Services.

"This has been a failure. If I were president, I would choose someone else because there needs to be accountability for higher health care costs, more measles deaths, losing elimination status, and no progress on processed foods," Cassidy said on CBS News.

Democratic senators Angela Alsobrooks and Patty Murray have also called for Kennedy's removal.

Alsobrooks (Maryland) condemned the loss of measles elimination status and called Kennedy's tenure a disgrace. She had called for his resignation or dismissal in May 2025. Her resolution of disapproval against Kennedy now has 28 Senate co-sponsors.

Senator Richard Blumenthal (Connecticut) has demanded answers over the alleged suppression of a CDC warning about measles risks during pregnancy, while criticising the administration's vaccine policies.

Murray (Washington) has blamed Trump and Kennedy's leadership for the loss of elimination status and repeatedly called for Kennedy's removal.

Governors Demand Kennedy's Removal

Democratic governors have also blamed Kennedy for the setback. New York Governor Kathy Hochul said the loss of measles elimination status contradicted Kennedy's promise to make America healthy again.

"RFK Jr. promised to 'Make America Healthy Again.' Now America has lost its measles-free status for the first time in 26 years," Hochul said.

"A disgraceful display of incompetence from the nation's highest public health office," she added.

Pennsylvania Governor Josh Shapiro blamed vaccine misinformation and skepticism for the setback. "There is a clear line from the misinformation, vaccine skepticism, and incompetence of RFK Jr. to this devastating news and very real consequences," Shapiro said.

Kentucky Governor Andy Beshear explicitly demanded Kennedy's removal. "This dangerous setback was 100% avoidable and is the result of one person: RFK Jr.," Beshear said. "Remove him now."

An HHS spokesperson rejected the governors' criticism in a statement to Fox News Digital, calling their attacks "baseless" and arguing that declining vaccination rates predated the Trump administration.

The spokesperson said the administration remained focused on expanding vaccine access, closing immunisation gaps and assisting state and local officials with outbreak investigations.

What Has RFK Jr. Said?

Kennedy has vowed to stop measles outbreaks and restore the country's elimination status while continuing to recommend vaccination.

"We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status," Kennedy said in a statement.

"I continue to recommend MMR vaccination as the most effective way to prevent measles," he added.

End of Article

Hope For Alzheimer's-Related Psychosis? Schizophrenia Drug Reduces Hallucinations & Delusions In Recent Trial

Updated Nov 19, 2026 | 08:00 PM IST

SummaryBristol Myers Squibb's schizophrenia drug Cobenfy, made by combining xanomeline and trospium chloride, reportedly showed promising results in controlling psychosis symptoms in patients with Alzheimer's disease.
Schizophrenia Drug Shows Promise Against Hallucinations And Delusions In Alzheimer's Patients

Credit: AI

A schizophrenia drug has reportedly proven effective in fighting manic symptoms like hallucinations and delusions that accompany Alzheimer's disease. The finding has sparked hope to treat one of the most distressing symptoms complications of dementia.

The drug, Cobenfy (xanomeline and trospium chloride), developed by Bristol Myers Squibb (BMS), is currently being investigated for treating psychosis that patients with Alzheimer's disease may experience. The preliminary findings from two Phase 3 clinical studies showed improvements in hallucinations, delusions and the severity of the overall disease among participants who received the drug.

The findings were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. Cobenfy is currently approved in the US for schizophrenia in adults, not for Alzheimer's-induced psychosis.

Findings From The Clinical Trial

Also read: Experimental Alzheimer's Drug Slows Cognitive Decline By 38% In A Two-Year Trial: How Does It Work?

The findings came from two studies within BMS's Phase 3 ADEPT clinical development programme.

In the ADEPT-1 study, 273 participants completed a 12-week treatment period in which patients knew they received Cobenfy.

Researchers observed a mean reduction of 12 points in participants' hallucination and delusion scores, which was measured using the Neuropsychiatric Inventory-Clinician (NPI-C) scale. Their overall scores of disease severity also improved.

A separate study, ADEPT-3, evaluated long-term safety and tolerability of the drug. Among 401 participants, 273 completed the 52-week treatment period. Their hallucination and delusion scores also improved.

However, these findings came from open-label treatment trials, which means that participants and researchers knew that the drug was being administered. More reliable evidence will come from the blinded parts of the ADEPT programme, which evaluate the treatment's efficacy against a control group.

What Is Alzheimer's-Related Psychosis?

Also read: 'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Alzheimer's disease is a progressive neurological condition that damages brain cells and gradually affects memory, thinking, behaviour and the ability to perform everyday activities. Some people with Alzheimer's also develop psychosis, which can present with symptoms like hallucinations and delusions.

Hallucinations occur when someone sees, hears or experiences things that are not actually present. For instance, a person may see people around them who are not actually there or hear voices that others cannot hear.

Delusions involve strongly believing something that is not true. For example, an Alzheimer's patient with psychosis may be convinced that family members are stealing from them, that their partner is being unfaithful or that someone is trying to harm them.

According to BMS, approximately 30–50% of people with Alzheimer's experience psychosis during the course of the disease.

These symptoms can be distressing for patients as well as caregivers. Researchers also observed faster cognitive and functional decline in patients with psychosis. This increased caregiver burden and a greater likelihood of institutionalisation.

Despite the severity of Alzheimer's-induced psychosis, there are currently no FDA-approved medicines for treating it.

More About Cobenfy

Cobenfy works differently from other antipsychotic medicines, which usually target dopamine receptors in the brain. Cobenfycombines two drugs: xanomeline and trospium chloride.

Xanomeline activates muscarinic receptors, specifically M1 and M4 receptors, which regulate communication between brain cells, cognition and behaviour. By targeting these receptors, xanomeline regulates parts of brain that are involved in psychiatric symptoms.

Trospium chloride is added to reduce unwanted effects of xanomeline outside the brain, especially those involving the peripheral nervous system.

In the 12-week ADEPT-1 treatment period, 56.6% of participants experienced at least one adverse event due to the drug. Serious adverse events were reported in 5% of participants, while 4.4% stopped the treatment because of side effects.

In the longer-term ADEPT-3 study, adverse events were reported in 65.1% of participants, serious adverse events in 7.7%, and discontinuations due to adverse events in 4.7%.

Cobenfy remains investigational for its use for Alzheimer's-related psychosis. The ongoing ADEPT programme includes more studies to assess its efficacy , dose and long-term safety. BMS is expected to share further findings along with important results placebo-based trials.

End of Article

India To Track 4 Infectious Disease Syndromes Across 70 Labs For Early Outbreak Warnings: How It Will Work

Updated Nov 19, 2026 | 07:00 PM IST

SummaryThe ICMR has launched a syndromic surveillance network across 70 VRDLs and IRDLs to strengthen early detection of infectious disease outbreaks and improve public health preparedness.
India To Track 4 Infectious Disease Syndromes Across 70 Labs For Early Outbreak Warnings: How It Will Work

Credit: iStock

India is strengthening its early-warning system for infectious disease outbreaks through a network of 70 Virus Research and Diagnostic Laboratories (VRDLs) and Infectious Disease Research and Diagnostic Laboratories (IRDLs).

Led by the Department of Health Research (DHR) and the Indian Council of Medical Research (ICMR), the initiative will introduce syndromic surveillance using real-time or near-real-time health data to identify potential outbreaks.

The initiative was launched at the third DHR-ICMR Health Research Excellence Summit.

"Syndromic Surveillance under the DHR Virus Research and Diagnostic Laboratories (VRDL) Scheme will create an early-warning network for outbreaks across 70 VRDLs and Infectious Disease Research & Diagnostic Laboratories (IRDLs)," ICMR announced.

The network will support epidemiological investigations and help authorities assess an outbreak's scale, geographical spread and speed of transmission.

Which 4 Infectious Disease Syndromes Will India Track?

Also read: ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?

As reported by Hindustan Times, the surveillance framework will focus on four major infectious disease syndromes:

  • Acute Febrile Illness (AFI): Including acute undifferentiated fever, fever with rash and fever with lymphadenopathy.
  • Acute Encephalitis Syndrome (AES): Conditions involving inflammation of the brain, often linked to infections.
  • Acute Respiratory Illness: Infections affecting the respiratory system.
  • Acute Diarrhoeal Disease: Infections causing diarrhoea.

ICMR has prepared syndrome-specific priority pathogen lists to guide doctors, laboratory specialists, epidemiologists and policymakers on testing and surveillance.

Why Does India Need Standardised Pathogen Testing?

A document outlining the framework, seen by the media outlet, points to limited countrywide data on pathogen prevalence and trends to guide surveillance policies.

As testing protocols differ between institutions and regions, many follow disease-specific approaches and sequential testing, leading to "missing out on common or critical pathogens".

Such gaps can hamper patient care and aggravate public health challenges, including antimicrobial resistance (AMR).

To address this, ICMR has identified priority pathogens responsible for critical infectious disease syndromes in India.

Read More: New COVID Variant PJ.2.1 Spreading Globally: Is India At Risk, Are There New Symptoms?

How Will ICMR Prioritise Infectious Disease Pathogens?

The priority lists were developed through 44 meetings involving clinicians, laboratory specialists and epidemiologists from across the country, the report said.

Expert groups reviewed scientific literature from India and similar settings, considering pathogen prevalence, emerging trends, outbreak potential, disease elimination targets and the availability of diagnostics and treatments.

The pathogens have been classified into four categories:

  • Priority 1A: Commonly detected pathogens that are important to identify before starting treatment.
  • Priority 1B: Other commonly detected pathogens in clinical settings.
  • Priority 2: Less common pathogens found in clinical settings.
  • Priority 3: Rare pathogens that may require specialised laboratory testing and surveillance.

Testing priorities will also depend on local and seasonal risks. Endemic pathogens will receive greater attention in affected regions, while outbreak-prone infections will be prioritised during outbreaks. Seasonal pathogens will be given greater attention during periods such as the post-monsoon and flooding seasons.

Animal exposure, including contact with cats, rats and rabbits, and suspected exotic infections will also influence testing priorities.

The initiative aims to improve pathogen detection, strengthen clinical diagnosis and help authorities identify unusual disease patterns before they escalate into larger outbreaks.

End of Article